When “Low Risk” Products Become High Risk: Lessons from Sunscreens & Listed Medicines
Many sponsors assume that products classified as “low risk” require minimal pharmacovigilance oversight. In Australia, this assumption is particularly common among sponsors of listed medicines, complementary products, and over-the-counter consumer healthcare products.
However, regulatory classification does not eliminate safety risk. In fact, some of the most visible regulatory issues in recent years have involved products traditionally perceived as low risk, particularly sunscreens and listed medicines.
The challenge for sponsors is understanding that “low risk” in a regulatory context does not mean “low scrutiny,” “low exposure,” or “low reputational impact.”
Regulatory Classification vs Real-World Risk
In Australia, listed medicines are generally considered lower-risk products because they contain permitted ingredients and make lower-level indications. Similarly, many consumer healthcare products such as sunscreens are widely available without prescription and are used routinely by the general public.
From a regulatory perspective, these products may have less complex pre-market requirements compared with prescription medicines.
From a pharmacovigilance perspective, however, the risk profile can change significantly depending on:
Volume of consumer use
Vulnerable populations
Public visibility
Social media amplification
Quality issues or contamination events
Patterns of adverse events
A product with relatively low inherent toxicity may still become a significant regulatory concern if safety issues emerge at scale.
Sunscreens: A Clear Example of Escalating Risk
Sunscreens are often perceived by consumers and sponsors as straightforward, low-risk products. Yet they occupy a unique position within the Australian market due to both widespread use and strong public health importance.
This means that even isolated safety concerns can attract substantial attention.
Recent years have demonstrated how quickly issues involving sunscreens can escalate, particularly where concerns relate to:
Product contamination
Stability failures
Labelling inconsistencies
Consumer-reported adverse reactions
Questions regarding efficacy or ingredient safety
Because sunscreens are used daily by large sections of the population, including children and individuals with sensitive skin, the potential impact of any issue becomes amplified.
In these situations, sponsors are expected to demonstrate:
Effective adverse event collection processes
Timely escalation pathways
Robust quality and recall procedures
Clear coordination between quality assurance and pharmacovigilance functions
Sponsors that treat sunscreens as operationally “simple” products may find themselves unprepared when scrutiny increases.
Listed Medicines and the Illusion of Low Regulatory Exposure
Listed medicines are another area where sponsors frequently underestimate pharmacovigilance obligations.
A common misconception is that because listed medicines are lower-risk products under the ARTG framework, pharmacovigilance requirements are minimal. In reality, sponsors are still responsible for:
Collecting and assessing adverse events
Reporting serious adverse reactions to the TGA within required timelines
Maintaining appropriate records
Ensuring adequate oversight of outsourced activities
Monitoring product safety on an ongoing basis
The challenge is compounded by the fact that many listed medicine sponsors are smaller organisations without dedicated PV departments. Safety responsibilities are often fragmented across customer service, regulatory affairs, quality, or marketing teams.
This creates operational vulnerabilities, particularly where:
Staff are not trained to recognise adverse events
Consumer complaints are not appropriately assessed
Vendor oversight is limited
PV procedures exist only on paper
In practice, these gaps may remain unnoticed until triggered by a regulatory questionnaire, inspection, or safety issue.
High Consumer Exposure Changes the Risk Equation
One of the most overlooked aspects of “low risk” products is exposure volume.
A product with a low rate of adverse events can still generate substantial safety concern if millions of consumers are using it regularly.
For example:
Mild but recurring skin reactions associated with a sunscreen
Hepatic concerns linked to long-term supplement use
Consumer misuse driven by marketing claims
When exposure is widespread, even low-frequency events can become significant from both a regulatory and reputational perspective.
This is particularly relevant in the age of social media, where isolated consumer experiences can rapidly gain visibility and attract regulatory attention.
Reputation Risk Often Exceeds Regulatory Risk
For many sponsors, the greatest consequence of a safety issue is not necessarily regulatory action, but reputational damage.
Products marketed as “natural,” “safe,” or “gentle” are especially vulnerable to public scrutiny when adverse events emerge. Consumer trust can deteriorate quickly, particularly where sponsors appear unprepared, dismissive, or slow to respond.
In some cases, relatively small PV deficiencies can escalate because:
Adverse event reports were not escalated internally
Follow-up information was not collected
Complaint handling processes were disconnected from PV
Public responses lacked transparency
Sponsors should therefore view pharmacovigilance not only as a compliance requirement, but as a core component of brand protection.
The Importance of Proportionate Pharmacovigilance
The solution is not to apply overly burdensome PV systems to every product. Rather, sponsors should ensure that their systems are proportionate, functional, and aligned with actual risk exposure.
For listed medicines and sunscreens, this generally means:
Clear adverse event intake pathways
Defined escalation procedures
Appropriate staff training
Oversight of third-party providers
Integration between PV and quality systems
Ongoing review of safety trends
Importantly, systems should reflect how products are used in the real world, not simply how they are classified within the regulatory framework.
The distinction between “low risk” and “high risk” products is not always as clear as it appears. Sunscreens and listed medicines demonstrate how quickly products with relatively low regulatory barriers can become subject to significant scrutiny when safety concerns emerge.
For sponsors, the key lesson is simple: low-risk classification should never result in low-risk thinking.
Pharmacovigilance systems should be designed not only around regulatory categories, but around consumer exposure, operational realities, and the potential impact of safety issues when they occur.
